Results 71 to 80 of about 626 (142)

Diagnosis and management of central hypersomnias

Therapeutic Advances in Neurological Disorders, 2012
Central hypersomnias are diseases manifested in excessive daytime sleepiness (EDS) not caused by disturbed nocturnal sleep or misaligned circadian rhythms.
Karel Sonka, Marek Susta
doaj   +1 more source

Treatment of the Narcoleptiform Sleep Disorder in Chronic Fatigue Syndrome and Fibromyalgia with Sodium Oxybate [PDF]

, 2010
This study investigates the response of the underlying sleep disorder associated with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FM) to treatment.
Broadman, Melissa, Spitzer, A. Robert
core   +1 more source

Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture

International audienceMany components of sleep are disrupted in patients with narcolepsy, including sleep quality, sleep architecture, and sleep stability (ie, frequent awakenings/arousals and frequent shifts from deeper to lighter stages of sleep ...
Dauvilliers, Yves, Plazzi, Giuseppe, Roth, Thomas, Black, Jed, Bogan, Richard, K   +4 more
core   +2 more sources

Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia

Medicines, 2018
Background: Symptoms of sleep disorders, such as disturbances in sleep initiation and continuity, are commonly reported in patients with schizophrenia, especially in the acute phase of illness. Studies have shown that up to 80% of patients diagnosed with
Lauren Stummer, Marija Markovic, Megan E. Maroney   +2 more
doaj   +1 more source

The pharmacokinetics of once-nightly controlled- release Sodium Oxybate (FT218): overview of results from four phase 1 studies

, 2019
Introduction: Sodium oxybate is an effective treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The approved effective doses of sodium oxybate are 6, 7.5 and 9 g per night, divided in two doses - the first taken at ...
Thorpy, M, Winkelman, J, Monteith, D, Corser, B, Dubow, J, Roth, Thomas, Grassot, J   +6 more
core  

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level

, 2018
International audienceMedication development for alcohol relapse prevention or reduction of consumption is highly challenging due to meth-odological issues of pharmacotherapy trials.
van denBrink W, Simon N, Gual, A., Lesch, Otto-Michael, Söderpalm, Bo,, Walter, Henriette, Perney P, Walter, H., Dematteis M, Aubin HJ, Caputo F, Sommer WH, Rehm, Jurgen, van den Brink, Wim, Paille, François, Rehm, J. rgen, Walter H, Spanagel, Rainer, Reynaud, M., Lesch OM, Rehm, J., Mann, Rainer, Benyamina, A., Mann, Karl, Paille F, Söderpalm B, Benyamina, Amine, Nutt, David, Perney, Pascal, Nutt, D., van den Brink, W., Paille, F., Caputo, Fabio, Simon, Nicolas, Spanagel R, Nutt D, Sommer, Wolfgang H., Lesch, O. M., Reynaud, Michel, Aubin, Henri-Jean, Maremmani, Icro, Gual, Antoni, Addolorato G, Söderpalm, Bo, Gual A, Caputo, F., Aubin, H. J., Benyamina A, Maremmani I, Dematteis, M., Reynaud M, Mann, K., Perney, P., Sommer, W. H., Addolorato, Giovanni, Rehm J, Addolorato, G., Mann K, Spanagel, R., Maremmani, I., Simon, N., Addolorato G., Mann, Wolfgang, Dematteis, Maurice, Caputo F.   +64 more
core   +1 more source

Criteria for Gauging Response to Sodium Oxybate for Narcolepsy

, 2017
Our objective was to define responder criteria using an anchor-based approach for frequency of cataplexy attacks and excessive daytime sleepiness in narcolepsy patients undergoing sodium oxybate treatment. We used pooled data from two randomized, placebo-
Terri E. Weaver (7931498), Alana D. Steffen (7931495), Chinglin Lai (5169872)   +2 more
core  

New developments in the management of narcolepsy

Nature and Science of Sleep, 2017
Vivien C Abad, Christian Guilleminault Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University Outpatient Center, Redwood City, CA, USA Abstract: Narcolepsy is a life-long, underrecognized sleep disorder ...
Abad VC, Guilleminault C
doaj  

Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial

Sleep Medicine: X
Background: Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (P 
Michael J. Thorpy, Clete A. Kushida, Richard Bogan, Akinyemi O. Ajayi, Bruce C. Corser, Jennifer Gudeman   +5 more
doaj   +1 more source

Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis

Nature and Science of Sleep, 2023
Shuqin Zhan,1 Hui Ye,2 Ning Li,1 Yimeng Zhang,1 Yueyang Cheng,1 Yuanqing Wang,1,3 Shimin Hu,1 Yue Hou1 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China; 2Ignis Therapeutics (Shanghai ...
Zhan S, Ye H, Li N, Zhang Y, Cheng Y, Wang Y, Hu S, Hou Y   +7 more
doaj